Equal pay and transparency Directive 2023/970 – duties for employers
Publication date: March 18, 2025
Equal pay and transparency is one of the fundamental pillars of social justice and gender equality policy in the European Union. Despite many years of efforts to eliminate the pay gap, there are still significant differences in the earnings of women and men performing the same work or work of equal value. In response to these challenges, on 10 May 2023, the European Parliament and the Council of the European Union adopted Directive 2023/970, which aims to strengthen the application of the principle of equal pay through pay transparency mechanisms and more effective enforcement of the law.
The new regulations require employers to disclose remuneration criteria, report pay differences and implement tools that allow employees to pursue their rights in the event of suspected discrimination. Another significant change is the transfer of the burden of proof to the employer in proceedings concerning unequal pay.
AI FACTORY IN POLAND
Publication date: March 17, 2025
The European Union wants to create a federated, secure and hyper-connected ecosystem of data infrastructure and services that will enable:
- development of innovative AI technologies,
- development of close cooperation and coordination with other European countries,
- making supercomputers available to the scientific and industrial sectors,
- increasing European technological independence,
- development of new AI applications in medicine, industry, cybersecurity and other sectors.
Following this decision, in July 2021, the Commission issued a regulation establishing the European High Performance Computing Joint Undertaking.
Limitations of trade in medicinal products in Poland
The limits of trade in medicinal products in Poland are strictly defined by legal regulations. The main source regulating the sale of medicines is the Act of 6 September 2001 – Pharmaceutical Law (Journal of Laws of 2024, item 686, as amended) (hereinafter referred to as “Pharmaceutical Law”). Art. 2, point 32 of the aforementioned Act states that a medicinal product is a substance or mixture of substances presented as having properties for the prevention or treatment of diseases occurring in humans or animals or administered for the purpose of making a diagnosis or for the purpose of restoring, improving or modifying the physiological functions of the body through pharmacological, immunological or metabolic action. Pharmaceutical Law presents principles that define the rules of trade in such products.
KIELTYKA GLADKOWSKI TAKES PART IN WEBINAR ‘WHAT’S NEXT FOR UKRAINE’ – REARM EU, COLLATERAL OF FROZEN ASSETS, DRONES PRODUCTION, NATO BUFFER – HILLARY RODHAM CLINTON, STEPHEN BIDDLE, IAN BREMMER, TIMOTHY FRYE, VICTORIA NULAND, KEREN YARHI-MILO
Publication date: March 07, 2025
On 6 March 2025 KIELTYKA GLADKOWSKI took part in the webinar: IGP Rapid Response: What’s Next for Ukraine.
